Genoskin Launches MANTIS, a Spatial Biology Imaging Platform Dedicated to Skin Immunology
Genoskin, a biotechnology company that leverages live ex vivo human skin to test therapeutic and non-therapeutic products, today announces the launch of MANTIS ®, a new spatial biology imaging platform dedicated to skin immunology. This new offer was developed by Dr. Nicolas Gaudenzio and his team at Inserm. Dr. Gaudenzio was recently appointed CSO (Chief Scientific Officer) at Genoskin.
MANTIS is the only spatial biology solution specifically designed to analyze human skin and the only one backed by multiple validated ex vivo human skin platforms. This unique service provides researchers with 3D multiplexed imaging of human skin tissue and enables an unbiased complete immune profiling of skin tissue within its spatial context. As the tissue’s spatial architecture may affect disease pathology and treatment response, MANTIS is uniquely positioned to resolve and evaluate the immunomodulatory effects of molecules on skin; upon injection, topical application or systemic administration.
MANTIS incorporates technology licensed from Inserm – the French National Institute of Health and Medical Research. This strategic agreement broadens Genoskin’s service offer to the global biotech and pharmaceutical industry and brings a unique spatial biology solution to the market. MANTIS will integrate seamlessly with Genoskin’s existing data generation platforms to complete the company’s offer of cutting-edge AI-based analyses, including next-generation RNA sequencing and high-performance immunoassay analysis.
These technologies position Genoskin as a key partner for biopharmaceutical companies, enabling new drug development processes with time and cost savings.
Dr. Nicolas Gaudenzio and his team developed MANTIS in partnership with Genoskin’s R&D department. Dr. Gaudenzio is a world-renowned expert in immunology and allergic skin inflammation, with over 40 peer-reviewed publications and patents. As principal investigator at Inserm, he leads a research group at the Infinity Institute (Toulouse Institute for Infectious and Inflammatory Diseases, France). As Genoskin’s CSO, Nicolas heads its R&D team, with a focus on immunology to support the launch of innovative solutions for the biopharmaceutical industry.
Pascal Descargues, Ph.D., CEO of Genoskin, said: “We are thrilled to launch the new MANTIS platform that will allow clients in the pharmaceutical industry to study the effects of drugs, including vaccines, on the cutaneous immune system. MANTIS relies on the extensive work done by Dr. Gaudenzio and his team to develop this powerful, transversal tool. Joining forces with the Infinity Lab at Inserm to build the MANTIS platform and signing this strategic license agreement has been an amazing journey. We also plan to pursue new co-developments with academic labs. Following the launch of our ISR platform this year, the first ex vivo human skin platform to study injection site reactions, we are continuing our strategic shift and fulfilling Genoskin’s mission of transforming the way drugs are developed today, using human skin as a reliable tool to generate relevant human data.”
The spatial omics market was estimated at $225.81M (€195M) in 2020 and is predicted to grow at a CAGR of ten per cent to reach $484.22M (€418M) in 2028. Most expert companies are located in the US and provide spatial biology devices, not services like MANTIS. Numerous spatial omics companies are focused on cancer research and diagnosis; Genoskin’s offer is much more versatile.
People In This Post
Companies In This Post
- Tvardi Therapeutics Appoints John Kauh, M.D. as Chief Medical Officer Read more
- Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S. Read more
- Spectrum Science Receives Strategic Investment from Knox Lane to Fuel Continued Growth Read more
- Synergy Health Partners Selects Dr. Richard L. Makowiec as Chief Surgical Officer Read more
- TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials Read more